65,437 trials
Colorectal Neoplasms · Neuroendocrine Tumors · Cholangiocarcinoma
Primary: Number of Participants With Adverse Events — 42 participants
Human Volunteers
Primary: Comparison Between INVOS Monitoring and Electromyography — 73; 46 % of StcO2
Trauma
Primary: Base Deficit </= -6 — 12 participants
Papillomavirus Infections
Primary: Percentage of Participants Who Seroconvert to Each of the HPV Types Contained in the Vaccine — 100; 100; 100; 100 Percentage of Participants
Ovarian Cancer
Primary: 2-year Progression-free Survival — 40; 40 percentage of participants
Human Immunodeficiency Virus Infection
Primary: Percentage of Participants With Adverse Drug Reactions — 37.73 percentage of participants
Epilepsy
Primary: Cmax - the Maximum Plasma Concentration — 21960.6; 25414.8; 931.8; 1062.6 ng/mL
Anxiety Disorders
Primary: Effect of Alprazolam Versus Placebo on BOLD fMRI During Emotion Processing
Human Papillomavirus · Prevention
Primary: Mother's Intention to Vaccinate Daughter Against HPV — 1.53; 1.29 units on a scale
Epilepsy
Primary: QTcI - QT Interval Individually Corrected for Heart Rate - Day 5 — -8.05; -6.15; -2.77; -4.39 msec
Nerve Block
Primary: Median Effective Concentration(EC50) — 5.7; 2.9 mg/ml(the concentration of lidocaine)
Cervical Cancers · Vulvar Cancers · Vaginal Cancers
Primary: Percentage of Participants Who Experience an Injection-site Adverse Event (AE) - Base Study — 91.1; 43.9 Percentage of Participants
Metastatic Breast Cancer
Primary: Progression-Free Survival (PFS) — 4.8 months
Papillomavirus Infections
Primary: Geometric Mean Titers (GMTs) of the Antibody Response to Each of the Human Papillomavirus (HPV) Types Contained in V503 — 1637.9; 1725.0; 1170.3; 1212.6 milli Merck…
Obesity
Primary: The Effect of Sucralose on Insulin Concentration (Area Under the Curve; AUC) — 57,192; 68,647 (pmol • min •L-1) — p=0.025